UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 14,842 Shares of Sotera Health (NASDAQ:SHC)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its holdings in Sotera Health (NASDAQ:SHC) by 5.4% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 261,995 shares of the company’s stock after selling 14,842 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Sotera Health were worth $4,375,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the business. Wedmont Private Capital raised its holdings in shares of Sotera Health by 6.5% in the third quarter. Wedmont Private Capital now owns 10,915 shares of the company’s stock valued at $169,000 after buying an additional 664 shares during the last quarter. First Citizens Bank & Trust Co. raised its holdings in shares of Sotera Health by 5.0% in the third quarter. First Citizens Bank & Trust Co. now owns 14,287 shares of the company’s stock valued at $239,000 after buying an additional 677 shares during the last quarter. CWM LLC raised its holdings in shares of Sotera Health by 86.1% in the second quarter. CWM LLC now owns 2,146 shares of the company’s stock valued at $25,000 after buying an additional 993 shares during the last quarter. GAMMA Investing LLC raised its holdings in shares of Sotera Health by 125.0% in the third quarter. GAMMA Investing LLC now owns 2,988 shares of the company’s stock valued at $50,000 after buying an additional 1,660 shares during the last quarter. Finally, TD Asset Management Inc raised its holdings in shares of Sotera Health by 1.5% in the second quarter. TD Asset Management Inc now owns 123,454 shares of the company’s stock valued at $1,465,000 after buying an additional 1,800 shares during the last quarter. 91.03% of the stock is owned by institutional investors.

Analyst Ratings Changes

SHC has been the subject of a number of research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on Sotera Health in a report on Friday, December 6th. They set a “neutral” rating and a $14.00 price objective for the company. Finally, Citigroup boosted their price objective on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.08.

Sotera Health Stock Performance

Shares of NASDAQ:SHC opened at $13.40 on Friday. The stock has a market capitalization of $3.80 billion, a P/E ratio of 53.04 and a beta of 1.96. Sotera Health has a 1-year low of $10.71 and a 1-year high of $17.44. The business has a 50-day moving average price of $14.71 and a two-hundred day moving average price of $14.13. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). The company had revenue of $285.47 million for the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a return on equity of 42.27% and a net margin of 6.31%. Sotera Health’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.18 earnings per share. Equities analysts predict that Sotera Health will post 0.61 earnings per share for the current year.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.